Elan Novis

Elan Novis

Auto-generated profile, based on publicly available information

Elan Novis

Melanoma Institute Australia, Sydney, Australia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2024 in Surgery
Verified
Journal Article
Closed access
ENElan Novis
Elan Novis
AGAnthony Glover
Anthony Glover
JGJohn Grady
John Grady
ASAudrey Silvestri
Audrey Silvestri
STSubotheni Thavaneswaran
Subotheni Thavaneswaran
DTDavid M. Thomas
David M. Thomas

15 November 2023 in Surgery in Practice and Science
Verified
Journal Article
Open access
ENElan Novis
Elan Novis
TKTae Jun Kim
Tae Jun Kim
CGChahaya Gauci
Chahaya Gauci
JMJasmine Mui
Jasmine Mui
YGYijun Gao
Yijun Gao
NGNatalia Garibotto
Natalia Garibotto
Sentinel lymph node biopsy (SLNB) is the standard of care for axillary staging in patients with clinically lymph node negative early breast cancer, reducing the need for axillary lymph node dissection (ALND) and its associated risks. Intra-operative frozen section is a method of rapid pathological assessment of the sentinel node to identify the presence of metastatic disease and potentially avoid the need for a second operation in patient who will require an axillary lymph node dissection. A retrospective review of a prospectively collected breast cancer database was performed. All patients with breast cancer who underwent SLNB and/or ALND at our institution, between May 1st 2017 to June 1st 2022 were identified. There were 565 patients who were included in the study. Intra-operative frozen section was able to accurately identify 71% of patients who had macrometastasis in their sentinel lymph node, thus allowing them to immediately proceed to ALND and avoid a second operation. In patient who had a false negative frozen section result, only 6.5% required ALND. The majority of false negative results were due to isolated tumour cells or micrometastasis, and therefore would not have required further intervention. Intra-operative frozen section of sentinel lymph node biopsy in breast cancer is useful in reducing the need for a second operation, allowing staging of the axilla to occur more efficiently and with high diagnostic accuracy.

3 October 2024 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
ENElan Novis
Elan Novis
RPRoneil Parikh
Roneil Parikh
RMRobert Mechera
Robert Mechera
LDLouella Davey
Louella Davey
NGNatalia Garibotto
Natalia Garibotto
Lymphomas associated with breast implants are rare, and the majority of these are anaplastic large-cell lymphomas of T-cell origin. Very uncommonly B-cell lymphomas associated with implants have been described, and examples of invasive disease are even less commonly reported. This report discusses one such 72-year-old patient who presented with pain and concerns about implant rupture on imaging. Histopathology demonstrated an invasive EBV + large B-cell lymphoma associated with bilateral silicone implants inserted 20 years previously. This was managed with implant explantation, capsulectomy and adjuvant chemotherapy.

3 December 2024 in Diseases of the Colon & Rectum
Verified
Journal Article
Closed access
TKTae-Jun F.R.A.C.S. Kim
Tae-Jun F.R.A.C.S. Kim
ENElan F.R.A.C.S. Novis
Elan F.R.A.C.S. Novis
PLPeter J.M. F.R.A.C.S. Lee
Peter J.M. F.R.A.C.S. Lee
SKSascha M.Physio. Karunaratne
Sascha M.Physio. Karunaratne
MCMollie M.Nur. Cahill
Mollie M.Nur. Cahill
MSMichael J. D.Med.Sci Solomon
Michael J. D.Med.Sci Solomon
BACKGROUND: Pelvic mucosal melanomas, including anorectal and urogenital melanomas, are rare and aggressive, with a median overall survival of up to 20 months. Pelvic mucosal melanomas behave differently from their cutaneous counterparts and present late with locoregional disease, making pelvic exenteration its only curative surgical option. OBJECTIVE: This study aimed to evaluate the survival outcomes after pelvic exenteration in pelvic mucosal melanomas at Royal Prince Alfred Hospital. DESIGN: Retrospective case series from a prospectively collected pelvic exenteration database from October 1994 to November 2023. SETTING: Royal Prince Alfred Hospital (quaternary institution), Camperdown, New South Wales, Australia. PATIENTS: Seven patients undergoing pelvic exenteration for pelvic mucosal melanoma. MAIN OUTCOME MEASURES: Overall survival, disease-free survival, and complication rates. RESULTS: Of the 7 patients, most were women (n = 5; 71.4%) and had a median age of 65 years (range, 36–79). Five patients (71.4%) underwent pelvic exenteration for primary pelvic mucosal melanoma, 3 of which were anorectal and 2 vaginal melanomas. Two patients (28.6%) had recurrent anorectal melanoma and received neoadjuvant radiotherapy after an initial wide local excision. Three patients (42.9%) required total pelvic exenteration, whereas 2 required a central pelvic exenteration (28.6%). The remaining procedures included central and lateral pelvic exenteration and anterior, central, and lateral pelvic exenteration. The median length of hospital stay was 19.7 days. Five patients had postoperative complications with 1 major complication (Clavien-Dindo grade IIIa). At the completion of the study, there were 4 mortalities. Mean survival was 23.6 months (range, 2–100) with a recurrence rate of 83%. The median time to recurrence was 3 months, despite 6 patients (85.7%) having R0 resections. Distant recurrence, specifically to bone, the lungs, and the liver, was most common. LIMITATIONS: Small study cohort due to rarity of disease, limiting generalizability. CONCLUSIONS: Pelvic exenteration for pelvic mucosal melanoma appears to help control local disease as recurrence is most commonly distant or regional. See Video Abstract. RESULTADOS DE SUPERVIVENCIA EN PACIENTES SOMETIDOS A EXENTERACIÓN PÉLVICA POR MELANOMAS DE LA MUCOSA PÉLVICA: ESTUDIO RETROSPECTIVO AUSTRALIANO DE UNA SOLA INSTITUCIÓN: ANTECEDENTES: Los melanomas de la mucosa pélvica (MM), incluidos los melanomas anorrectales y urogenitales, son raros y agresivos, con una supervivencia global media de hasta 20 meses. Los melanomas de la mucosa pélvica se comportan de manera diferente a sus contrapartes cutáneas y se presentan tardíamente con enfermedad locoregional, lo que hace que la exenteración pélvica (EP) sea su única opción quirúrgica curativa. OBJETIVO: Este estudio tuvo como objetivo evaluar los resultados de supervivencia tras la exenteración pélvica en melanomas de la mucosa pélvica en el Royal Prince Alfred Hospital. DISEÑO: Serie de casos retrospectivos de una base de datos de exenteración pélvica recopilada prospectivamente desde octubre de 1994 hasta noviembre de 2023. ESCENARIO: Royal Prince Alfred Hospital (institución cuaternaria), Camperdown, Nueva Gales del Sur, Australia. PACIENTES: Siete pacientes sometidos a exenteración pélvica por melanoma de la mucosa pélvica. PRINCIPALES MEDIDAS DE RESULTADOS: Supervivencia general, supervivencia libre de enfermedad y tasas de complicaciones. RESULTADOS: De los siete pacientes, la mayoría fueron mujeres (n = 5, 71,4%) y tenían una edad media de 65 años (rango 36-79). Cinco pacientes (71,4%) fueron sometidos a una exenteración pélvica por melanoma primario de la mucosa pélvica; tres de los cuales eran melanomas anorrectales y dos vaginales. Dos pacientes (28,6%) tuvieron melanoma anorrectal recurrente y recibieron radioterapia neoadyuvante después de una escisión local amplia inicial.Tres pacientes (42,9%) requirieron una exenteración pélvica total, mientras que dos requirieron una exenteración pélvica central (28,6%). Los procedimientos restantes fueron una exenteración pélvica central y lateral; junto con una exenteración pélvica anterior, central y lateral. La duración media de la estancia hospitalaria fue de 19,7 días. Cinco pacientes tuvieron complicaciones postoperatorias con una complicación mayor (Clavien-Dindo IIIa). Al finalizar el estudio, hubo cuatro muertes. La supervivencia media fue de 23,6 meses (rango 2-100) con una tasa de recurrencia del 83%. El tiempo medio hasta la recurrencia fue de tres meses, a pesar de que seis pacientes (85,7%) tuvieron resecciones R0. La recurrencia distante, es decir, en hueso, pulmón e hígado fueron la más comúnes. LIMITACIONES: Cohorte de estudio pequeña debido a la rareza de la enfermedad, lo que limita la generalización. CONCLUSIÓN: La exenteración pélvica para el melanoma de la mucosa pélvica parece ayudar a controlar la enfermedad local, ya que la recurrencia es más comúnmente distante o regional. (Traducción—Dr Osvaldo Gauto)

9 December 2024 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
ENElan Novis
Elan Novis
ASAhmad Sulaiman
Ahmad Sulaiman
JSJonathan Stretch
Jonathan Stretch
DCDavid Chung
David Chung
KLKevin London
Kevin London
MRMichael Rtshiladze
Michael Rtshiladze

3 December 2025 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
ENElan Novis
Elan Novis
MRMervi Rautalin
Mervi Rautalin
AAAlexander C. J. van Akkooi
Alexander C. J. van Akkooi